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Abstract 
Purpose:We sought to demonstrate that a single systemic administration of L19mTNFa (a fusion 
protein constituted by the scFv L19 specific for the oncofetal ED-B domain of fibronectin and 
tumor necrosis factor a,TNFa) in combinationwithmelphalan induced complete and long-lasting 
tumor eradication in tumor-bearing mice and triggered the generation of a specificTcell ^ based 
immune response that protects the animals from a second tumor challenge, as well as from 
challenges with syngeneic tumor cells of different histologic origin. 
Experimental Design and Results:Treatment with L19mTNFa, in combinationwithmelphalan, 
induced complete tumor regression in 83% of BALB/c mice withWEHI-164 fibrosarcoma and 
33%of animalswith C51coloncarcinoma.All curedmice rejected challengeswith the sametumor 
cells and, in a very high percentage of animals, also rejected challengeswith syngeneic tumor cells 
of different histologic origin.I n adoptive immunity transfer experiments, the splenocytes from 
tumor-curedmice protected naivemice both fromC51colon carcinoma and fromWEHI-164 
fibrosarcoma. 
S imilar results were also obtained in adoptive immunity transfer experiments using 
severely immunodepressed mice.Exper iments using depleted splenocytes showed that Tcells 
play amajor role in tumor rejection. 
Conclusions:The results show that the selective targeting of mTNFa to the tumor enhances 
its immunostimulatory properties to the point of generating a therapeutic immune response 
against different histologically unrelated syngeneic tumors.T hese findings predicate treatment 
approaches for cancer patients based on the targeted delivery of TNFa to the tumor vasculature. 
 
Introduction 
Fibronectin is an extracellular matrix component widely expressed in a variety of normal tissues 
and body fluids. Different fibronectin isoforms could be generated by the alternative splicing of the 
fibronectin pre-mRNA, a process that is modulated by cytokines and extracellular pH(1, 2). The 
complete type III repeat ED-B may be included or omitted in the fibronectin molecule (3). ED-B is 
highly conserved in different species, having 100% homology in all the mammalians studied thus 
far (human, rat, and mouse), and 96% homology with a similar domain in chicken. The fibronectin 
isoform containing ED-B (B-FN) is immunohistochemically undetectable in normal adult tissues, 
with the exception of tissues undergoing physiologic remodeling (e.g., endometrium and ovary) and 
during wound healing (4). By contrast, its expression in tumors and fetal tissues is high (4, 5). 
Furthermore, we showed that B-FN is a marker of angiogenesis (6, 7), and that endothelial cells 
invading tumor tissues migrate along extracellular matrix fibers containing B-FN (8). The function 
of B-FN, however, is still unclear. Fukuda et al. (9) generated mice lacking the ED-B exon and 
showed that, whereas B-FN is highly expressed throughout early embryogenesis, ED-B-deficient 
mice developed normally and were fertile. We previously reported on the possibility to selectively 
target tumor vasculature using a human recombinant antibody specific for B-FN, L19(scFv), in both 
experimental animal models and cancer patients (8, 10–14). This observation paved the way for the 
antibody’s use in vivo for both diagnostic and therapeutic purposes. Indeed, the selective targeted 
delivery of cytokines to the ED-B domain of fibronectin using L19(scFv) dramatically enhances 
their anticancer properties (15–19). Building on this finding, the fusion protein L19-interleukin-2 is 
now in phase I/II clinical trials in patients with different kinds of solid tumors. Tumor necrosis 
factor-a (TNFa) is a pleiotropic cytokine (20) composed of three noncovalently linked TNFa 
monomers, f17.5 kDa each, that yield a compact bell-shaped homotrimer (21). TNFa exerts its 
major antitumor effects mainly via a preferential toxicity for the endothelial cells of the tumor-
associated vasculature and through an increase of the antitumor immune response. The toxicity for 
endothelial cells of the tumor vasculature leads to extensive thrombosis and destruction of tumor 
vasculature resulting in extensive tumor necrosis (22, 23). Furthermore, TNFa increases vascular 
permeability (24) and reduces the tumor’s interstitial fluid pressure (25), a process pivotal to 
facilitating the penetration of antitumor agents at the tumor site. Like other primary 
proinflammatory signals, TNFa promotes the maturation of dendritic cells in vivo and their 
migration to draining lymph nodes (26), and, in some cases, fosters long-lasting protective 
immunity (27, 28). Although TNFa is one of the most potent antitumor cytokines, its unacceptable 
toxic side effects have prevented its systemic administration at therapeutically effective doses. To 
date, the clinical use of TNFa has been limited to locoregional applications, such as ‘‘isolated limb 
perfusion,’’ in combination with melphalan for the treatment of nonresectable high-grade sarcoma 
and melanoma (29–31). TNFa is also being evaluated for the therapy of nonresectable liver tumors 
by isolated hepatic perfusion (32). These results prompted a number of studies aimed at decreasing 
TNFa toxicity without modifying its antitumor properties, thereby allowing its use not only for 
locoregional treatments but also for systemic therapy. Resulting strategies include the production of 
engineered TNFa mutants (33), encapsulation of TNFa in liposomes (34), and the targeted delivery 
to tumors of TNFa through its coupling to specific ligands (17, 35–38). These last endeavors seem 
to represent the most promising strategy. We recently generated the fusion protein L19mTNFa (17), 
consisting of mouse TNFa (mTNFa) and the human antibody fragment L19(scFv) directed to the 
ED-B domain of fibronectin. When injected i.v. into tumor-bearing mice, this fusion protein 
selectively accumulates around the tumor vasculature and, 48 hours after injection, the dose of 
L19mTNFa in the tumor is roughly 35 times higher than the dose achieved with a control fusion 
protein in which mTNFa is conjugated to an irrelevant scFv (TN11). Here, we show that a single 
systemic administration of L19mTNFa and melphalan in mice bearing two histologically unrelated 
syngeneic tumors induces complete and long lasting tumor eradication and triggers the generation 
of a specific T cell–based immune response that protects the animals from a second tumor 
challenge, as well as from challenges with syngeneic tumor cells of different histologic origin.  
 
Materials and Methods 
Animal tumor models. WEHI-164 mouse fibrosarcoma (3  106 cells; European Collection of 
Animal Cell Cultures, Sigma-Aldrich, Milan, Italy), C51 mouse colon adenocarcinoma (0.5  106 
cells; kindly provided by Dr. M.P. Colombo, Department of Experimental Oncology, Istituto 
Nazionale Per Lo Studio E La Cura Dei Tumori, Milan, Italy), all of BALB/c origin, were s.c. 
implanted in the left flank of immunocompetent syngeneic BALB/c mice or of severe combined 
immunodeficiency (SCID) beige mice. All mice were 8 to 10 weeks old and purchased from Harlan 
UK (Oxon, United Kingdom). The tumor volume was determined using the following formula: (d)2 
 D  0.52; where d and D are the short and long dimensions (cm) of the tumor, respectively, 
measured with a caliper (8). Housing, treatment, and sacrifice of animals followed national 
legislative provisions (Italian law no. 116; January 27, 1992) for the protection of animals used for 
scientific purposes. Lung metastases were established in BALB/c mice injecting 75  103 C51 cells 
in 100 AL PBS [20 mmol/L NaH2PO4, 150 mmol/L NaCl (pH 7.4)] into the tail vein. When 
respiratory distress was present and/or a 10% weight loss was recorded over a 24-hour period, the 
mice were sacrificed and the lungs were infused through the trachea with 15% India ink solution. 
Only normal lung parenchyma was stained black by the ink solution, whereas the tumor metastases 
appeared white and could be counted.  
Tumor therapy. Groups of tumor-bearing mice (when the tumors reached a volume off0.2 cm3) 
received an injection in their tail vein of the fusion proteins L19mTNFa or TN11mTNFa (the 
expression, purification, and characterization of the fusion proteins have previously been reported; 
ref. 17) or of recombinant mTNFa (2  107 units/mg, kindly provided by Dr. A. Corti, Department 
of Oncology, Cancer Immunotherapy and Gene Therapy Program, San Raffaelle M. Scientific 
Institute, Milan, Italy), in 100 AL of PBS. As already reported (17), in the therapeutic protocols 
with a single compound, 1 pmol/g of L19mTNFa, TN11mTNFa, or mTNFa was used, whereas 0.7 
pmol/g was used in combination with other drugs. The group of controls received 100 AL of PBS 
only. Lyophilized melphalan (Alkeran, Glaxo Smith Kline, Research Triangle Park, NC) was 
reconstituted (10 mg/mL) in the solvent provided by the manufacturer immediately before use and, 
after further dilution in PBS, was administered i.p. (4.5 Ag/g in 400 AL). The weight of the animals 
and the tumor volume were recorded at 24-hour intervals before and after treatments. Toxicity was 
evaluated on the basis of weight loss, as reported by Borsi et al. (17). The mice were sacrificed 
when the tumor reached a volume of 1.5 cm3. TNFa cytolytic assays were carried out in the 
presence of actinomycin D as described by Borsi et al. (17). Quadruplicates were carried out and the 
results expressed as a percentage of cell viability (average F SD) versus mTNFa (pg/mL).  
Adoptive immunity transfer experiments (Winn assay), cell-mediated cytotoxicity, and 
enzyme-linked immunospot assay. WEHI-164- or C51 tumor–cured mice were given a s.c. 
booster dose in the contralateral flank with cells derived from the same tumors (3  106, WEHI-
164; 0.5  106, C51) and, after 12 days, the total splenocytes were obtained, following the 
procedure described by Meazza et al. (39). To establish the amount of effector splenocytes able to 
protect naı¨ve mice against WEHI-164 or C51 tumor, different effector-tumor cell ratios (E/T), 
from 5:1 to 0.3:1, were calculated. In the adoptive immunity transfer experiments using splenocytes 
from WEHI-164 tumor–cured mice, an E-T ratio of 1:1 was used with WEHI-164 tumor (3  106 
cells) whereas with C51 tumor (0.5  106 cells) an E/T ratio of 5:1 was used. For in vitro depletion, 
negative magnetic separation (Clin ExVivo Dynabeads, Dynal Biotech ASA, Oslo, Norway) was 
used, following the manufacturer’s instructions. The magnetic beads were coated with anti- CD4 
(clone GK1.5, ATCC), anti-CD8 (clone 2.43, ATCC), anti-B (clone RA3-3A1/6.1, ATCC) rat 
monoclonal antibodies (mAb) or rabbit anti-asialo-GM1 antiserum (Wako Chemicals GmbH, 
Dusseldorf, Germany). The recovered splenocytes underwent a second specific antibody incubation 
and a complement-mediated depletion step with 1:10 rabbit complement (Cederlane, Hornby, 
Ontario, Canada). Cell depletion was assessed by immunofluorescence and cytofluorimetric 
analysis by indirect staining of B cell subset (primary mAb, clone RA3- 6B2, Southern Biotech, 
Birmingham, AL; secondary antibody, FITCconjugated goat F(abV)2 anti-rat IgG; Southern 
Biotech) and by direct staining for CD4 (FITC-conjugated YTS 191.1.2 mAb; Immunotools, 
GmbH, Germany), CD8 (PE-conjugated YTS 169.4 mAb; Immunotools) and natural killer (FITC-
conjugated DX-5 mAb, Caltag Laboratories, Burlingame, CA) subsets. Isotype-matched mAbs of 
unrelated specificity were used as controls. Analysis was done on a FACScan (Becton Dickinson, 
Milan, Italy). Cell-mediated cytotoxicity was evaluated by a standard (4 hour) 51Cr release assay in 
mixed lymphocyte-tumor cell cultures, using either immune splenocytes obtained from WEHI-164 
tumor–cured mice, 12 days after the third WEHI-164 tumor challenge, or splenocytes from naı¨ve 
mice as described by Croce et al. (40). Inhibition test of lysis with concanamycin A (0.2 Ag/mL, 
Sigma-Aldrich) was done as described by Seki et al. (41). Enzyme-linked immunospot assay was 
conducted using ex vivo splenocytes from either naı¨ve or WEHI-164 tumor-cured mice as 
described by Croce et al. (40). A >2-fold increase in the number of spots compared with the control 
was considered a positive response. 
 
 Results 
L19mTNFa in combination with melphalan cures different murine tumors. Tumor-bearing 
mice were treated with a single i.v. administration of L19mTNFa (0.7 pmol/g) in combination with 
melphalan (4.5 Ag/g), given i.p., as described in Materials and Methods. For control molecules, we 
substituted L19m TNFa with mTNFa or TN11mTNFa. Two murine experimental models, WEHI-
164 fibrosarcoma and C51 colon carcinoma, were used for their different in vitro sensitivities to 
mTNFa. In fact, as shown in Fig. 1A, in the presence of actinomycin D, WEHI-164 cells are f300 
times more sensitive than C51 cells to mTNFa. The treatment with L19mTNFa and melphalan 
induced complete and irreversible tumor eradication in 83% of mice bearing WEHI-164 
fibrosarcoma (74 out of 89 mice treated in different experiments carried out using identical 
conditions; Fig. 1B) and in 33% (6 out of 18) of mice bearing C51 colon carcinoma (Fig. 1C). On 
the contrary, using mTNFa (Fig. 1C) or TN11mTNFa (data not shown), in combination with 
melphalan, no tumor eradication was observed in C51 colon carcinoma–bearing mice (0 out of 9 in 
both cases), whereas in the case of WEHI-164 fibrosarcoma, eradication was achieved in 54.5% (6 
out of 11) of the mice treated with mTNFa and melphalan (data not shown) and in 61% of the mice 
treated with TN11mTNFa and melphalan (22 out of 36 mice treated in different experiments carried 
out using identical conditions; Fig. 1B). The therapeutic efficacy on WEHI-164 fibrosarcoma– 
bearing mice of L19mTNFa or melphalan alone is reported in Fig. 1B. Only a moderate increase of 
survival time of the tumorbearing mice was observed in either case. In order to assess whether the 
combined treatment with L19mTNFa and melphalan induced tumor eradication in 
immunocompromised mice, we s.c. induced WEHI-164 tumor formation in SCID beige mice. In 
these animals, the treatment resulted in no tumor eradication but only in tumor growth retardation 
(Fig. 1D), indicating that the treatment ‘‘per se’’ was not sufficient to cure the tumor, and strongly 
suggesting that the immune system plays a crucial role in the antitumor activity of L19mTNFa.  
Cured mice reject challenges of syngeneic tumors of different histologic origin. To better 
investigate the immune system’s involvement in tumor eradication induced by the treatments, we 
assessed whether WEHI-164-cured and C51-cured mice were able to reject tumors on challenge. 
One hundred percent of the cured mice rejected challenges with the same tumor cells. In the case of 
WEHI-164 fibrosarcoma, the mice resisted challenges with 15  106 cells (five times the dose used 
to induce the tumor in 100% of the mice; Table 1A). Moreover, 100% of C51 colon carcinoma–
cured mice rejected challenges with histologically unrelated syngeneic WEHI-164 fibrosarcoma. 
(Table 1B). In WEHI-164 tumor–cured mice, the challenge with the histologically unrelated 
syngeneic C51 colon carcinoma was rejected by 60% of the animals, when the injected number of 
tumor cells was 0.5  106 (a cell dose inducing tumors in 100% of the animals), and by 30% of the 
mice challenged with 3  106 tumor cells (Table 1A). The ability of WEHI-164 tumor–cured mice 
to reject challenges with syngeneic tumor cells of different histologic origins increased if the cured 
mice were first challenged with the same tumor (WEHI-164). In fact, in WEHI-164 tumor–cured 
mice, after the first homologous tumor challenge, a new challenge with either C51 (3  106 cells) 
or RENCA (renal cell carcinoma, 1  106 cells) tumors was rejected by 100% of the mice (Table 
1A). This finding was not restricted to s.c. implants, but also to lung metastasis generated by i.v. 
injection of the C51 tumor cells (Fig. 2; Table 1A). 
 Immunologic correlates of tumor rejection: in vitro and in vivo studies. To study the 
contribution of different host cellular effector mechanisms responsible for tumor clearance and for 
tumor immunity induced by L19mTNFa/melphalan therapy, we evaluated the ability of total spleen 
cells from several WEHI- 164 tumor–cured mice to kill different tumor cell lines (WEHI- 
164 fibrosarcoma, C51 colon carcinoma, RENCA renal carcinoma, C26 colon carcinoma) in vitro 
in a classical 4-hour 51Cr release assay. Splenocytes, assayed at 12 and 30 days after an in vivo 
WEHI-164 tumor rechallenge, were restimulated in vitro for 5 days with irradiated WEHI-164 
tumor cells. As shown in Fig. 3A, at 12 days, high specific lysis was detected on WEHI-164 target 
cells and on all other syngeneic tumor cell lines tested. At day 30, a strong specific lysis was still 
found for WEHI-164 tumor cells and, to a lesser extent, for C51 targets (Fig. 3B). The addition 
during the test of concanamycin A, a specific inhibitor of perforin-dependent lysis, resulted in a 
dramatic decrease of specific cells lysis (66% for WEHI-164 and 100% for C51 target cells, 
respectively; Fig. 3B), indicating that CD8+ CTL effectors play an important role in the killing 
process. We then evaluated whether effector splenocytes, at 12 days after WEHI-164 rechallenge, 
presented on restimulation in vitro, a preferential production of IFN-g or of interleukin-4, 
representative, respectively, of type 1- and type 2–specific cytokines. For this purpose, we analyzed 
the frequencies of freshly isolated spleen cells by enzyme-linked immunospot assay. As shown in 
Fig. 4A and B, ex vivo immune spleen cells specifically recognized all four different syngeneic 
tumor cells tested, and high frequencies of effector cells were detected for both IFN-g (Fig. 4A) and 
interleukin-4 (Fig. 4B); thus, indicating that the tumor immunity was associated with a strong 
induction of both T helper 1 and T helper 2 types of responses. We also evaluated mTNFa 
secretion, upon in vitro tumor stimulation, by total spleen cells at 30 days after WEHI-164 tumor 
rechallenge. As shown in Fig. 4C, we found that the basal level of mTNFa secretion by 
unstimulated splenocytes from tumor-rejecting mice was higher compared with naı¨ve splenocytes; 
moreover, 4 days after in vitro antigen stimulation using WEHI-164 and C51 tumor cells, the 
amount of mTNFa in the supernatant of the spleen cells of tumor-rejecting mice was more than 
twice that found in the supernatant of naı¨ve spleen cells. Finally, we investigated by adoptive 
transfer experiments whether immune splenocytes of WEHI-164 tumor–bearing mice cured with 
L19mTNFa and melphalan, and rejecting a subsequent homologous tumor challenge, were able to 
protect naı¨ve animals from tumor formation. Mixtures of tumor cells and splenocytes at different 
proportions were s.c. coinjected into naı¨ve mice (Winn assay). Results showed that immune 
splenocytes in the E/T ratio of 1:1 were fully competent in protecting naı¨ve mice (100%, 30 out of 
30) from WEHI-164 tumor formation. Moreover, these mice acquired complete resistance to 
homologous tumor challenges carried out 45 days after the Winn assay using up to 10  106 
WEHI-164 cells (Fig. 5A). To determine whether immune splenocytes from WEHI-164 tumor–
cured mice were able to protect naı¨ve animals against the histologically unrelated C51 colon 
carcinoma, a Winn assay was done using 0.5  106 C51 tumor cells and an E/T ratio of 5:1. In 
these conditions, 80% (16 out of 20) of the mice completely rejected the C51 tumor cells (Fig. 5B). 
Transferred immune splenocytes also induced resistance to WEHI-164 tumor formation (E/T = 1:1) 
in 78% (seven of seven) SCID beige mice (Fig. 5C) that were able to reject a new tumor challenge 
up to 3 months after the adoptive transfer. Adoptive transfer experiments were also done using 
immune splenocytes after in vitro depletion of specific cell subsets. The results shown in Fig. 5D 
indicate that removal of B cells or natural killer cells did not meaningfully alter the ability of the 
immune splenocytes to reject WEHI-164 tumor (100% rejection, eight out of eight, in B cell–
depleted; and 87% rejection, seven out of eight, in natural killer–depleted spleen cells). Also, 
removal of CD8+ cells did not determine any dramatic change in the ability of immune splenocytes 
to reject WEHI tumor: in fact, six out of eight animals were protected. On the contrary, immune 
splenocytes depleted of CD4+ cells protected only two out of eight animals. These results reveal the 
fundamental role exerted by T cells, the CD4+ subset in particular, in the adoptive rejection 
process.  
 
Discussion  
The findings presented in this study show that the therapeutic combination of the fusion protein 
L19mTNFa and melphalan, given as a single systemic administration, results in a high rate of 
complete and long-lasting tumor eradication without any apparent adverse side effects (>8 months 
with no sign of tumor recurrence at the writing of this article) in both the WEHI-164 fibrosarcoma 
(83%) and the C51 colon carcinoma (33%) models. Treating the tumor-bearing mice with 
melphalan and mTNFa alone or fused to an irrelevant antibody, we obtained, in the case of the C51 
colon carcinoma, no tumor eradication and, 
in the case of WEHI-164 fibrosarcoma, tumor eradication at a reduced rate compared with what was 
achieved with L19mTNFa treatment. The different responses of these two tumors to 
L19mTNFa/melphalan therapy may be due to one of two reasons: either the different sensitivities of 
the two tumor cell lines to mTNFa, or the higher immunogenicity of WEHI-164 fibrosarcoma with 
respect to C51 colon carcinoma. This issue is presently under investigation. We also observed a T 
cell–mediated immune response able to reject further tumor challenges in the mice cured using 
melphalan and mTNFa or TN11mTNFa (data not shown). Thus, the combined treatment of tumor-
bearing mice with melphalan and L19mTNFa, which induces a much higher rate of complete and 
longer-lasting tumor eradication compared with melphalan combined with mTNFa alone or fused to 
an irrelevant antibody, enhances the intrinsic anticancer activity of TNFa. The attempt to treat 
WEHI-164 fibrosarcoma grown in SCID beige mice did not result in any cure, but only in a 
retardation of tumor growth (Fig. 1D), due to the antitumor effects of melphalan and of TNFa 
exerted mainly on the angiogenic endothelial cells of the tumor vasculature (22, 23). In addition, all 
cured mice were resistant to tumor challenge, and the tumor rejection was not limited to the original 
tumor that was subjected to therapy, but was extended to histologically unrelated s.c. tumors and 
metastases. Moreover, the results of Winn assays reported here (Fig. 5) show that the splenocytes 
from cured mice protect naı¨ve animals also from histologically 
unrelated syngeneic tumors. Taken together, these findings show that, in addition to the cytotoxic 
effects of TNFa on the tumor vasculature, the immune system plays a role in the processes leading, 
first, to tumor cure and, subsequently, to the acquisition of immunologic memory and effector 
functions, two traits that are instrumental to the recognition and rejection of tumors. These findings 
also indicate that the immunologic response is likely directed against tumor-associated antigens 
(TAA) shared by the different tumors tested. Previous studies by Curnis et al. (36) showed the 
enhancement of TNFa antitumor immunotherapeutic properties by its targeted delivery to amino 
peptidase CD13; this approach achieved only sporadic cases of complete cure, however, and 
rejection of challenges was limited to only few cases of the same tumor from which the animals 
were originally cured. The enhancement of TNFa immunotherapeutic activity generated by its 
targeted administration to B-FN may be due to the cytokine’s high level of accumulation in the 
tumor environment, which, in concert with high local concentrations of melphalan (42), induces 
massive tumor cell killing with high levels of tumor antigens available for antigen-presenting cells. 
Antigen-presenting cells infiltrating into the tumor site with the contribution of TNFa (that 
stimulates endothelial cell adhesion of circulating phagocytic cells) subsequently migrate to lymph 
nodes where they can present TAAs to CD4+ T helper cells (27, 28). Thus, the availability of large 
amounts of TAAs from the necrotic area of the tumor, in conjunction with an 
efficient TAA uptake by antigen-presenting cells, may result in the strong triggering and 
maintenance of the antitumor immune response observed here. The results of the present 
investigation reveal the fundamental role of T cells, and especially of the CD4+ subset, as effectors 
of the antitumor immune response generated by L19mTNFa in combination with melphalan. The 
role of effector CD8+ CTLs, clearly present as shown by the strong cytolytic response against 
tumor targets of different histologic origin (Fig. 3), seems to be less important in the in vivo 
rejection of WEHI-164 tumor in the Winn assay with CD8-depleted immune splenocytes (Fig. 5D). 
No major role in the effector response seems to be played by either B cells or natural killer cells 
(Fig. 5D). CD4+ T helper cells are required for the optimal induction of both humoral and cellular 
effector mechanisms (43). T helper–derived cytokines, particularly T helper 1–type cytokines, are 
fundamental for the maturation and functional competence of CTLs and B cells, as well as for the 
activation of antigen-presenting cells (44). Our results also indicate that in L19mTNFa/melphalan 
tumor–cured mice CD4+ T cells produce large amounts of IFN-g which, in addition to its important 
effects on the triggering and maintenance of immune effector cells, may exert an antiangiogenic 
effect and therefore play a role in the inhibition of tumor growth (45). It is noteworthy that the 
CD4+ T cells of tumor-rejecting mice also produce large amounts of interleukin-4, a T helper 2–
type cytokine. Although some authors report that polarized T helper 2 responses promote, rather 
than inhibit, tumor growth and spread (46, 47), other investigators have observed mixed T helper 
1/2 immune responses that correlate with the tumor rejection (44, 48). The potent T cell–mediated 
immune response against the different types of tumors achieved with this treatment indicates that 
the immune response is directed against TAAs shared by tumors of different histologic origin. In 
fact, the existence of TAAs shared by different types of tumor has been reported for both mouse and 
human tumors (49). Furthermore, considering that TNFa has also shown a potent adjuvant activity, 
L19TNFa could be systemically administered to cancer patients in combination with vaccination 
approaches. This prospect may represent the rationale for a new therapeutic strategy against human 
cancer based on the targeted delivery of TNFa to tumor blood vessels.  
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